ANGO Stock Overview
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$25.49|
|52 Week High||US$32.00|
|52 Week Low||US$13.68|
|1 Month Change||-13.21%|
|3 Month Change||-10.56%|
|1 Year Change||83.65%|
|3 Year Change||23.08%|
|5 Year Change||52.27%|
|Change since IPO||103.92%|
Recent News & Updates
Shareholders May Not Be So Generous With AngioDynamics, Inc.'s (NASDAQ:ANGO) CEO Compensation And Here's Why
Despite strong share price growth of 39% for AngioDynamics, Inc. ( NASDAQ:ANGO ) over the last few years, earnings...
Is AngioDynamics (NASDAQ:ANGO) Weighed On By Its Debt Load?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
|ANGO||US Medical Equipment||US Market|
Return vs Industry: ANGO exceeded the US Medical Equipment industry which returned 10.8% over the past year.
Return vs Market: ANGO exceeded the US Market which returned 20% over the past year.
|ANGO Average Weekly Movement||5.8%|
|Medical Equipment Industry Average Movement||7.3%|
|Market Average Movement||6.0%|
|10% most volatile stocks in US Market||15.1%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: ANGO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ANGO's weekly volatility (6%) has been stable over the past year.
About the Company
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits.
AngioDynamics Fundamentals Summary
|ANGO fundamental statistics|
Is ANGO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ANGO income statement (TTM)|
|Cost of Revenue||US$136.60m|
Last Reported Earnings
Aug 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.89|
|Net Profit Margin||-11.50%|
How did ANGO perform over the long term?See historical performance and comparison
Is AngioDynamics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: ANGO ($25.49) is trading above our estimate of fair value ($3.66)
Significantly Below Fair Value: ANGO is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ANGO is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: ANGO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ANGO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ANGO is good value based on its PB Ratio (2.3x) compared to the US Medical Equipment industry average (3.7x).
How is AngioDynamics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ANGO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ANGO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ANGO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ANGO's revenue (7.6% per year) is forecast to grow slower than the US market (10.1% per year).
High Growth Revenue: ANGO's revenue (7.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ANGO's Return on Equity is forecast to be low in 3 years time (2.3%).
How has AngioDynamics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ANGO is currently unprofitable.
Growing Profit Margin: ANGO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ANGO is unprofitable, and losses have increased over the past 5 years at a rate of 46.8% per year.
Accelerating Growth: Unable to compare ANGO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANGO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (51.2%).
Return on Equity
High ROE: ANGO has a negative Return on Equity (-7.86%), as it is currently unprofitable.
How is AngioDynamics's financial position?
Financial Position Analysis
Short Term Liabilities: ANGO's short term assets ($131.3M) exceed its short term liabilities ($52.1M).
Long Term Liabilities: ANGO's short term assets ($131.3M) exceed its long term liabilities ($67.7M).
Debt to Equity History and Analysis
Debt Level: ANGO has more cash than its total debt.
Reducing Debt: ANGO's debt to equity ratio has reduced from 23% to 5.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ANGO has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ANGO is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 24% per year.
What is AngioDynamics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ANGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ANGO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ANGO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ANGO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ANGO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jim Clemmer (57 yo)
Mr. James C. Clemmer, also known as Jim, has been the Chief Executive Officer, President and a Director of AngioDynamics, Inc. since joining it on April 04, 2016. Mr. Clemmer served as Group President of t...
CEO Compensation Analysis
Compensation vs Market: Jim's total compensation ($USD4.05M) is above average for companies of similar size in the US market ($USD2.29M).
Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.
Experienced Management: ANGO's management team is considered experienced (3.4 years average tenure).
Experienced Board: ANGO's board of directors are considered experienced (6.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ANGO insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
AngioDynamics, Inc.'s employee growth, exchange listings and data sources
- Name: AngioDynamics, Inc.
- Ticker: ANGO
- Exchange: NasdaqGS
- Founded: 1988
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$995.249m
- Shares outstanding: 38.65m
- Website: https://www.angiodynamics.com
Number of Employees
- AngioDynamics, Inc.
- 14 Plaza Drive
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/02 00:03|
|End of Day Share Price||2021/12/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.